CYD-4-61

Cat. No.: HY-148368: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.

For research use only. We do not sell to patients.

CYD-4-61 Chemical Structure

CAS No. : 1425944-33-7

Size	Price	Stock
5 mg		Ask For Quote & Lead Time
10 mg		Ask For Quote & Lead Time
25 mg		Ask For Quote & Lead Time
50 mg		Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Bax

Cellular Effect

Cell Line	Type	Value	Description	References
MCF-10A	IC₅₀	0.11 μM Compound: CYD-4-61	Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]
MCF7	IC₅₀	0.06 μM Compound: CYD-4-61	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]
MDA-MB-231	IC₅₀	0.07 μM Compound: CYD-4-61	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 33845235]

In Vitro

CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC₅₀s of 0.07 µM against triple-negative breast cancer MDA-MB-231 and 0.06 µM against ER-positive breast cancer MCF-7 cell lines, respectively^[1].
CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells^[1].
CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells^[1].
CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	MCF-10A, T47D, MCF-7, MDA-MB-231, and MDA-MB-468 cells
Concentration:	0.1, 1, and 10 μM
Incubation Time:	72 hours
Result:	Inhibited triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation and viability.

Western Blot Analysis^[1]

Cell Line:	MCF-7 and MDA-MB-231 cells
Concentration:	5 μM
Incubation Time:	0, 6, 12, 24, and 48 hours
Result:	Dose-dependently led to the upregulation of cleaved PARP-1, cleaved caspase 3, and downregulation of cyclin D1.

In Vivo

CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Triple-negative breast cancer MDA-MB-231 xenograft model in mice^[1]
Dosage:	2.5 mg/kg
Administration:	Intraperitoneal injection; once daily for 7 consecutive days
Result:	Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%.

Molecular Weight

359.38

Formula

C₂₁H₁₇N₃O₃

CAS No.

1425944-33-7

Appearance

Solid

Color

Light yellow to yellow

SMILES

NCCOC1=NC=CC=C1/C=C2C3=C(C4=C/2C=CC=C4)C=CC([N+]([O-])=O)=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (55.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7826 mL	13.9128 mL	27.8257 mL
5 mM	0.5565 mL	2.7826 mL	5.5651 mL
10 mM	0.2783 mL	1.3913 mL	2.7826 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2 mg/mL (5.57 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (282 KB) SDS (252 KB)

COA (260 KB) HNMR (137 KB) RP-HPLC (170 KB) LCMS (114 KB)

Handling Instructions (2659 KB)

References

[1]. Liu G, et al. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. Eur J Med Chem. 2019 Sep 15;178:589-605. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7826 mL	13.9128 mL	27.8257 mL	69.5642 mL
	5 mM	0.5565 mL	2.7826 mL	5.5651 mL	13.9128 mL
	10 mM	0.2783 mL	1.3913 mL	2.7826 mL	6.9564 mL
	15 mM	0.1855 mL	0.9275 mL	1.8550 mL	4.6376 mL
	20 mM	0.1391 mL	0.6956 mL	1.3913 mL	3.4782 mL
	25 mM	0.1113 mL	0.5565 mL	1.1130 mL	2.7826 mL
	30 mM	0.0928 mL	0.4638 mL	0.9275 mL	2.3188 mL
	40 mM	0.0696 mL	0.3478 mL	0.6956 mL	1.7391 mL
	50 mM	0.0557 mL	0.2783 mL	0.5565 mL	1.3913 mL

CYD-4-61 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CYD-4-611425944-33-7Bcl-2 FamilyApoptosistriple-negative breast cancer MDA-MB-231ER-positive breast cancer MCF-7 cellcytochrome cInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *